Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of doravirine + islatravir versus Biktarvy in treatment-naive adults with HIV-1
MOH_2020-12-24_009050Phase 3Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of doravirine, islatravir and bictegravir + emtricitabine + tenofovir alafenamide in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Merck & Co. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
doravirineislatravirbictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on MOH_2020-12-24_009050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-12-24_009050.